Rogelio Braceras, MD: Improving Costs, Comorbidities in T2D

June 24, 2018 7:17 pm

The Boehringer Ingelheim representative discusses how the future of empagliflozin research should shape out.

Category: News
About The Author
-
Previous

Zanetti et al; Birthweight, T2D, and Cardiovascular Disease
Next

Reversing T2D with a keto diet — Diet Doctor Podcast with Dr. Sarah Hallberg

Related Videos

Unleashing-the-Truth-Approaching-T2D-Treatment-as-a-Team-Sport

Unleashing the Truth: Approaching T2D Treatment as a Team Sport

Dont-manage-type-2-diabetes-reverse-it

Don’t manage type 2 diabetes, reverse it!

Preview-A-low-carb-diet-for-T2D-reversal-Dr.-Sarah-Hallberg

[Preview] A low-carb diet for T2D reversal – Dr. Sarah Hallberg

Unleashing-the-Truth-How-to-Put-T2D-Patients-Hearts-First

Unleashing the Truth: How to Put T2D Patients’ Hearts First

GLP-1-Agonist-Therapy-in-a-Patient-With-T2D-and-CVD

GLP-1 Agonist Therapy in a Patient With T2D and CVD

Type-2-diabetes-remission-Reducing-excess-fat-in-the-liver-might-be-the-keyteaser

Type 2 diabetes remission: Reducing excess fat in the liver might be the keyteaser